CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.62B, above the global median of $1.18B
- FinancialsAltman Z-Score 4.73: safe zone
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
5.76%Above 5Y avg (3.66%)
Annual Rate
CNY 1.10Paid annual
Payout Ratio
80.0%Moderate
Payback Period
17.3 yr
Last Ex-Dividend
Jun 11, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
10.84BCNY1.62B · vs all stocks (USD)
Trailing P/E
13.85xRevenue (TTM)
3.90BCNY582.71M · vs all stocks (USD)
Profit Margin
19.99%Beta
-0.0290xvs all stocks
52-Week Change
-13.48%vs all stocks
Market Capitalization
10.84BCNY1.62B · vs all stocks (USD)
Enterprise Value
9.73BCNY1.45B · vs all stocks (USD)
Trailing P/E
13.85xForward P/E
12.74xPrice to Sales (TTM)
2.78xPrice to Book (MRQ)
3.35xEnterprise to Revenue
2.49xEnterprise to EBITDA
10.25xGross Margin
79.68%Profit Margin
19.99%Operating Margin
27.03%Return on Assets (TTM)
9.42%Return on Equity (TTM)
24.63%Revenue (TTM)
3.90BCNY582.71M · vs all stocks (USD)
Revenue per Share (TTM)
6.89CNYUpdated Sep 21, 2026Quarterly Revenue Growth
-5.20%Gross Profit (TTM)
3.07BCNY458.21M · vs all stocks (USD)
EBITDA (TTM)
988.21MCNY147.57M · vs all stocks (USD)
Net Income (TTM)
780.21MCNY116.51M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-3.40%Operating Cash Flow (TTM)
921.64MCNY137.63M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
670.80MCNY100.17M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.10CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
5.76%vs all stocks
5-Year Average Dividend Yield
3.66%vs all stocks
Payout Ratio
80.00%Minority Interest (Equity)
35.33MCNYFY2025 · Dec 31, 2025Revenue
3.85BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
769.55MCNYFY2025 · Dec 31, 2025Gross Profit
3.08BCNYFY2025 · Dec 31, 2025Operating Income
838.46MCNY125.21M · vs all stocks (USD)
Pre-tax Income
879.47MCNYFY2025 · Dec 31, 2025Income Tax Expense
117.02MCNYFY2025 · Dec 31, 2025Net Income
762.45MCNYFY2025 · Dec 31, 2025EBIT
883.37MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
988.21MCNYFY2025 · Dec 31, 2025Research & Development
169.12MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.71BCNYFY2025 · Dec 31, 2025Other Operating Expenses
53.74MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
9.73MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.90MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.34CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.34CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
566.79MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
566.79MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
762.45MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-2.94MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
613.57MCNYFY2025 · Dec 31, 2025Free Cash Flow
564.27MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
382.84MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
762.45MCNYFY2025 · Dec 31, 2025Other Non-cash Items
6.86MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-202.22MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
46.49MCNYFY2025 · Dec 31, 2025Capital Expenditures
-49.31MCNYFY2025 · Dec 31, 2025Net Acquisitions
-672.55MCNYFY2025 · Dec 31, 2025Purchase of Investments
-20.00MCNYFY2025 · Dec 31, 2025Sale of Investments
63.45MCNYFY2025 · Dec 31, 2025Other Investing Activity
-507.72MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.19BCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
371.25MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-70.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-511.29MCNYFY2025 · Dec 31, 2025Other Financing Charges
-3.23MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-213.26MCNYFY2025 · Dec 31, 2025Shares Outstanding
567.12MSharesUpdated Sep 21, 2026Float Shares
434.18MSharesUpdated Sep 21, 2026% Held by Insiders
24.02%vs all stocks
% Held by Institutions
12.27%vs all stocks
Total Cash (MRQ)
1.57BCNY233.89M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.76CNYUpdated Sep 21, 2026Total Debt (MRQ)
420.68MCNY62.82M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1287xCurrent Ratio (MRQ)
1.18xBook Value per Share (MRQ)
5.70CNYUpdated Sep 21, 2026Total Assets
5.64BCNY841.55M · vs all stocks (USD)
Total Current Assets
2.28BCNYFY2025 · Dec 31, 2025Total Liabilities
2.20BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.36BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
84.01MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.12BCNYFY2025 · Dec 31, 2025Cash
382.82MCNYFY2025 · Dec 31, 2025Cash Equivalents
24.20KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
382.84MCNYFY2025 · Dec 31, 2025Other Short-term Investments
160.35MCNYFY2025 · Dec 31, 2025Accounts Receivable
430.40MCNYFY2025 · Dec 31, 2025Inventory
436.64MCNYFY2025 · Dec 31, 2025Accounts Payable
97.27MCNYFY2025 · Dec 31, 2025Short-term Debt
394.24MCNYFY2025 · Dec 31, 2025Other Current Liabilities
12.53MCNYFY2025 · Dec 31, 2025Long-term Debt
4.27MCNYFY2025 · Dec 31, 2025Common Stock (Book)
567.12MCNYFY2025 · Dec 31, 2025Retained Earnings
2.15BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.44BCNY513.09M · vs all stocks (USD)
Treasury Stock
12.57MCNYFY2025 · Dec 31, 202552-Week Low
18.90CNYUpdated Sep 21, 202652-Week High
23.65CNYUpdated Sep 21, 202652-Week Change
-13.48%vs all stocks
Beta
-0.0290xvs all stocks
50-Day MA
20.92CNYUpdated Sep 21, 2026200-Day MA
21.34CNYUpdated Sep 21, 2026Avg 10-Day Volume
5.06MSharesUpdated Sep 21, 2026Avg 30-Day Volume
10.17MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
1.38CNYUpdated Sep 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.73: safe zoneNotable
Altman Z-Score: 4.73
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.62B, above the global median of $1.18BNotable
Market cap (USD): 1,619,222,237.578Global Median: 1,180,223,658.953
Revenue is $582.71M, above the global median of $548.88MNotable
Revenue (USD): 582,709,954.199Global Median: 548,883,780.48
Levered free cash flow is $100.17M, above the global median of $18.73MNotable
Levered free cash flow (USD): 100,170,363.3Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Syndax Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rapport Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jingfeng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Forte Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GH Research plc
Tier 1ProductionApproval-Gated PipelineRule
Natco Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Opm Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Stoke Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Qingdao Haier Biomedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Hitit Bilgisayar Hizmetleri A.S.
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income GrowthPrice Below Mean With Profitability And Book Value
Nmdc Limited
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income GrowthPrice Below Mean With Profitability And Book Value
HDFC Asset Management Co. Ltd.
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income GrowthPrice Below Mean With Profitability And Book Value